SCHEMBL6314960

SCHEMBL6314960

Cc1ccsc1-c1noc(N)c1C(=O)NC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.36
MDM2 Q00987 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
LMNA P02545 1/20 0.36
CA1 P00915 5/20 0.35
CA2 P00918 5/20 0.35
CA4 P22748 5/20 0.35
CA7 P43166 5/20 0.35
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323085 0.83 RAB9A (0.40) GAARAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL6324723 0.81 POLB (0.36) GAARAB9ASMN1; SMN2NPC1POLB
SCHEMBL6322906 0.80 GAA (0.42) GAARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL6315855 0.80 POLB (0.38) GAARAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL6315558 0.80 GHSR (0.38) GAARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL6315866 0.79 KMT2A (0.46) GAARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL6315672 0.79 POLB (0.41) RAB9ASMN1; SMN2NPC1ALDH1A1HPGD
SCHEMBL6316220 0.79 TSHR (0.44) GAARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL6324184 0.79 ALDH1A1 (0.44) GAARAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL6317149 0.79 KMT2A (0.43) GAARAB9ASMN1; SMN2NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GAA 789/4885RAB9A 1754/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.